 NEW YORK, July 08, 2021 GLOBE NEWSWIRE -- GBS Nasdaq: GBS, a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it has been awarded a USD 4.7 million, Australian Federal Government scientific grant to fund the build out of a Biosensor manufacturing facility. This project has been identified as one of six National Manufacturing Priorities identified by the Government under Modern Manufacturing Strategy MMS. 